News >

Kite Unveils Novel BCMA-Directed CAR T-cell Therapy

Silas Inman @silasinman
Published: Friday, Apr 21, 2017

Gregor B Adams

Gregor B Adams

Chimeric antigen receptor (CAR)-modified T-cell therapies have shown immense promise for the treatment of patients with B-cell malignancies, prompting their exploration across various other blood disorders. These agents have primarily targeted CD19, with 2 currently being evaluated for approval by the FDA for types of non-Hodgkin lymphoma.

Overall, treatment with KITE-585 led to a near eradication of the tumors in the mouse models as compared with untransfused mice. Mice were treated at day 6, when their approximate tumor volume was 100 mm3. Those in the experimental arm had a rapid decline and elimination of the tumor whereas untreated mice continued to have rapidly growing tumors that eventually surpassed 500 mm3.

"When we infuse KITE-585 cells into these animals, we get complete ablation of these tumors cells," Adams said.

CAR T cells were found to be persistent in the study, with an initial spike that plateaued by week 2. The persistence of KITE-585 in the peripheral blood was similar to what was seen with a single copy of the human gene RPP30, showing that there was not a reduction in the cell's ability to proliferate normally.

Following these early preclinical findings, Kite plans to initiate a phase I study to explore the CAR T-cell therapy in patients with multiple myeloma. This study is anticipated to begin enrolling in 2017, according to the company.


  1. Adams GB, Feng J, Ghogha A, et al. Development of KITE-585: A fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma. In: Proceedings from the 2017 AACR Annual Meeting; Washington DC, April 1-5, 2017. Abstract 4979.
  2. Adams GB, Feng J, Ghogha A, et al. Selectivity and specificity of engineered T cells expressing KITE‑585, a chimeric antigen receptor targeting B cell maturation antigen (BCMA). In: Proceedings from the 2017 AACR Annual Meeting; Washington DC, April 1-5, 2017. Abstract 2135.
  3. Rossi J, Paczkowski P, Shen Y-W, et al. Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma. In: Proceedings from the 2017 AACR Annual Meeting; April 1-5, 2017; Washington, DC. Abstract 2990.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.